Literature DB >> 35819261

Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL.

Russell Moser1, James Annis2, Olga Nikolova3, Cliff Whatcott4, Kay Gurley1, Eduardo Mendez5, Kim Moran-Jones6, Craig Dorrell7, Rosalie C Sears7, Calvin Kuo8, Haiyong Han4, Andrew Biankin4, Carla Grandori9, Daniel D Von Hoff4, Christopher J Kemp1.   

Abstract

SIGNIFICANCE: This study utilizes functional genetic and pharmacological profiling of KRAS-mutant pancreatic adenocarcinoma to identify therapeutic strategies and finds that TFIIH inhibition synergizes with TRAIL to induce apoptosis in KRAS-driven pancreatic cancer. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35819261      PMCID: PMC9481717          DOI: 10.1158/0008-5472.CAN-21-4222

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  72 in total

Review 1.  TFIIH: when transcription met DNA repair.

Authors:  Emmanuel Compe; Jean-Marc Egly
Journal:  Nat Rev Mol Cell Biol       Date:  2012-05-10       Impact factor: 94.444

2.  tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c.

Authors:  M C Wei; T Lindsten; V K Mootha; S Weiler; A Gross; M Ashiya; C B Thompson; S J Korsmeyer
Journal:  Genes Dev       Date:  2000-08-15       Impact factor: 11.361

3.  Immortalization with telomerase of the Nestin-positive cells of the human pancreas.

Authors:  K M Lee; C Nguyen; A B Ulrich; P M Pour; M M Ouellette
Journal:  Biochem Biophys Res Commun       Date:  2003-02-21       Impact factor: 3.575

4.  A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer.

Authors:  Rohit Chugh; Veena Sangwan; Satish P Patil; Vikas Dudeja; Rajinder K Dawra; Sulagna Banerjee; Robert J Schumacher; Bruce R Blazar; Gunda I Georg; Selwyn M Vickers; Ashok K Saluja
Journal:  Sci Transl Med       Date:  2012-10-17       Impact factor: 17.956

5.  Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.

Authors:  Sonja M Wörmann; Liang Song; Jiaoyu Ai; Kalliope N Diakopoulos; Magdalena U Kurkowski; Kivanc Görgülü; Dietrich Ruess; Andrew Campbell; Claudio Doglioni; Duncan Jodrell; Albrecht Neesse; Ihsan E Demir; Angelica-Phaedra Karpathaki; Maxim Barenboim; Thorsten Hagemann; Stefan Rose-John; Owen Sansom; Roland M Schmid; Maria P Protti; Marina Lesina; Hana Algül
Journal:  Gastroenterology       Date:  2016-03-19       Impact factor: 22.682

6.  The complete structure of the human TFIIH core complex.

Authors:  Basil J Greber; Daniel B Toso; Jie Fang; Eva Nogales
Journal:  Elife       Date:  2019-03-12       Impact factor: 8.140

Review 7.  A compendium of potential biomarkers of pancreatic cancer.

Authors:  H C Harsha; Kumaran Kandasamy; Prathibha Ranganathan; Sandhya Rani; Subhashri Ramabadran; Sashikanth Gollapudi; Lavanya Balakrishnan; Sutopa B Dwivedi; Deepthi Telikicherla; Lakshmi Dhevi N Selvan; Renu Goel; Suresh Mathivanan; Arivusudar Marimuthu; Manoj Kashyap; Robert F Vizza; Robert J Mayer; James A Decaprio; Sudhir Srivastava; Samir M Hanash; Ralph H Hruban; Akhilesh Pandey
Journal:  PLoS Med       Date:  2009-04-07       Impact factor: 11.069

8.  Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.

Authors:  J Lemke; S von Karstedt; M Abd El Hay; A Conti; F Arce; A Montinaro; K Papenfuss; M A El-Bahrawy; H Walczak
Journal:  Cell Death Differ       Date:  2013-12-20       Impact factor: 15.828

9.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.

Authors:  Kristian Cibulskis; Michael S Lawrence; Scott L Carter; Andrey Sivachenko; David Jaffe; Carrie Sougnez; Stacey Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz
Journal:  Nat Biotechnol       Date:  2013-02-10       Impact factor: 54.908

10.  Clinical Trials in Pancreatic Cancer: A Long Slog.

Authors:  Thomas Enzler; Susan Bates
Journal:  Oncologist       Date:  2017-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.